Evidence map›Paper›PMID 37900896›Full record

ArticleMedical cannabis and cannabinoids

Medical Cannabis Alleviates Chronic Neuropathic Pain Effectively and Sustainably without Severe Adverse Effect: A Retrospective Study on 99 Cases.

Lan Kluwe, Christian Scholze, Lisa Marie Schmidberg, Julian Lukas Wichmann, Mihail Gemkov, Martin Julian Keller, Said C Farschtschi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical cannabis and cannabinoids. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Lan KluweDepartment of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christian ScholzeAlgea Care GmbH, Frankfurt, Germany.
Lisa Marie SchmidbergAlgea Care GmbH, Frankfurt, Germany.
Julian Lukas WichmannAlgea Care GmbH, Frankfurt, Germany.
Mihail GemkovAlgea Care GmbH, Frankfurt, Germany.
Martin Julian KellerAlgea Care GmbH, Frankfurt, Germany.
Said C FarschtschiDepartment of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Individual Development and Adaptive Education · DEUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Medical cannabis may provide a treatment option for chronic neuropathic pain. However, empirical disease-specific data are scarce. Methods: This is a retrospective observational study including 99 patients with chronic neuropathic pain. These patients received medical cannabis by means of inhaling dried flowers with tetrahydrocannabinol content of <12-22% at a maximal daily dose of 0.15-1 g. Up to six follow-ups were carried out at intervals of 4-6 weeks. Pain severity, sleep disturbance, general improvement, side effects, and therapy tolerance at the follow-up consultations were assessed in interviews and compared with the baseline data using non-parametric Wilcoxon signed-rank test. Results: Within 6 weeks on the therapy, median of the pain scores decreased significantly from 7.5 to 4.0 ( Conclusion: Medical cannabis is safe and highly effective for treating neuropathic pain and concomitant sleep disturbance.

Indexed as

CannabinoidsMedical cannabisNeuropathic painSide effectSleep disturbance

Identifiers

PMID37900896
PMCPMC10601926
OpenAlexW4387753849

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.